The safety of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Seminars in cancer biology, 2010. Elsevier: 377-83.
   Google Scholar
• Ponader S, Chen -S-S, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–1189.
   PubMed Web of Science ®Google Scholar
• Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120(24):4684–4691.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563–574.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639–1648.
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609–4614.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, et al. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85(6):1580–1589.
   PubMed Web of Science ®Google Scholar
• Cordone I, Masi S, Mauro FR, et al. P53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91(11):4342–4349.
   PubMed Web of Science ®Google Scholar
• Barnabas N, Shurafa M, Van Dyke DL, et al. Significance of p53 mutations in patients with chronic lymphocytic leukemia. Cancer. 2001;91(2):285–293.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New England J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood. 2015;126(18):2110–2117.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–3254.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175–1184.
   PubMed Web of Science ®Google Scholar
• Craxton A, Jiang A, Kurosaki T, et al. Syk and Bruton’s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J Biol Chem. 1999;274(43):30644–30650.
   PubMed Web of Science ®Google Scholar
• Tomlinson MG, Woods DB, McMahon M, et al. A conditional form of Bruton’s tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC gamma 2 in B cells. BMC Immunol. 2001;2(1): 1.
   PubMedGoogle Scholar
• Petro JB, Khan WN. Phospholipase C-γ2 couples Bruton’s tyrosine kinase to the NF-κB signaling pathway in B lymphocytes. J Biol Chem. 2001;276(3):1715–1719.
   PubMed Web of Science ®Google Scholar
• Spaargaren M, Beuling EA, Rurup ML, et al. The B cell antigen receptor controls integrin activity through Btk and PLCγ2. J Exp Med. 2003;198(10):1539–1550.
   PubMed Web of Science ®Google Scholar
• Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199–227.
   PubMed Web of Science ®Google Scholar
• Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014;10(6):957–967.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci. 2010;107(29):13075–13080.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287–6296.
   PubMed Web of Science ®Google Scholar
• Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor–microenvironment interactions by ibrutinib–findings from an investigator-initiated phase II study. Clin Cancer Res. 2016;22(7):1572–1582.
   PubMed Web of Science ®Google Scholar
• Berglöf A, Hamasy A, Meinke S, et al. Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 2015;82(3):208–217.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Imbruvica (ibrutinib) [prescribing information]. Sunnyvale CPIJ.
   Google Scholar
• Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015;75(5):907–916.
   PubMed Web of Science ®Google Scholar
• de Jong J, Skee D, Hellemans P, et al. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment. Leukemia & lymphoma. 2017;58(1):185–194.
   Google Scholar
• Mikudina B, Goodall M, Adler AI. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation. The Lancet Oncology. 2017;18(3):289–290.
   Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Barr P, Robak T, Owen CJ, et al. Updated efficacy and safety from the phase 3 resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128(22):234.
   Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (resonate-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–1418.
   PubMed Web of Science ®Google Scholar
• Montillo M, O’brien S, Tedeschi A, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the resonate study. Blood Cancer J. 2017;7(2):e524.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2015.
   Web of Science ®Google Scholar
• Quintela A, Sujobert P, Callet-Bauchu E, et al. Ibrutinib-induced lymphocytosis: cytological features. Acta Haematol. 2017;137(1):55–57.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–1817.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211.
   PubMed Web of Science ®Google Scholar
• McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–3830.
   PubMed Web of Science ®Google Scholar
• Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003;102(10):3592–3599.
   PubMed Web of Science ®Google Scholar
• Oda A, Ikeda Y, Ochs HD, et al. Rapid tyrosine phosphorylation and activation of Bruton’s tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood. 2000;95(5):1663–1670.
   PubMed Web of Science ®Google Scholar
• Liu J, Fitzgerald ME, Berndt MC, et al. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood. 2006;108(8):2596–2603.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991–3995.
   PubMed Web of Science ®Google Scholar
• Yang L, Beiggi S, Zhang Y, et al. High cumulative illness rating scale (CIRS) score in CLL correlates with short CLL telomere length and decreased survival. Blood. 2016;128(22):4362.
   Google Scholar
• Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib. Br J Haematol. 2017.  doi:10.1111/bjh.14660.
   Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778.
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Acharya U, et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17(1):31-7. e13..
   Web of Science ®Google Scholar
• Michallet AS, Campidelli A, Lequeu H, et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: a real‐world experience of 71 patients treated in France: a study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol. 2017;92:E105–E107.
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncology. 2015;1(1):80–87.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Furman RR, Coutre SE, et al.Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128(22):233.
   Google Scholar
• Jain P, Thompson PA, Keating M, et al. Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123:2268–2273.
   PubMed Web of Science ®Google Scholar
• Kunk PR, Mock J, Devitt ME, et al. Major bleeding with ibrutinib: more than expected. Blood. 2016;128(22):3229.
   Google Scholar
• Mato AR, Timlin C, Ujjani C, et al. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study. Br J Haematol. 2017. doi:10.1111/bjh.14540.
   Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (acp-196) in relapsed chronic lymphocytic leukemia. New England J Med. 2016;374(4):323–332.
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, Cull G, et al.Twice daily dosing with the highly specific BTK inhibitor, bgb-3111, achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Blood. 2016;128(22):642.
   Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England J Med. 2014;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting bcl2 with venetoclax in relapsed chronic lymphocytic leukemia. New England J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–1765.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in t lymphocytes. Blood. 2013;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–2219.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Jerussi T, Farooqui M, et al. Atypical pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940–1943.
   PubMed Web of Science ®Google Scholar
• de Jésus Ngoma P, Kabamba B, Dahlqvist G, et al. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg. 2015;78:424–426.
   Web of Science ®Google Scholar
• Kaur V, Mehta P, Johnsurd J, et al. Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. Blood. 2014;124(23):3503–3505.
   PubMed Web of Science ®Google Scholar
• Coutré SE, Furman RR, Flinn IW, et al. Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res. 2017;23:1149–1155.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506. blood-2014-2010-606038.
   PubMed Web of Science ®Google Scholar
• Iskierka-Jażdżewska E, Hus M, Giannopoulos K, et al. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). Leuk Lymphoma. 2017;1–4.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. New England J Med. 2014;370(24):2286–2294.
   PubMed Web of Science ®Google Scholar
• Landau D, Hoellenriegel J, Sougnez C, et al. Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition. Blood. 2013;122(21):866.
   Google Scholar
• Woyach JA. How I manage ibrutinib-refractory chronic lymphocytic leukemia. Blood. 2017;129(10):1270–1274.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469–1479. blood-2016-2006-719294.
   PubMed Web of Science ®Google Scholar
• Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7.
   Web of Science ®Google Scholar
• Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood. 2015;125:2062–2067. blood-2014-2009-603670.
   PubMed Web of Science ®Google Scholar
• Guo A, Lu P, Coffey G, et al. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget. 2017;8(8):12953.
   PubMed Web of Science ®Google Scholar
• Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–2786.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Matos T, Kim HT, et al. Idelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicities. Blood. 2015;126(23):497–497.
   Web of Science ®Google Scholar
• Louie CY, DiMaio MA, Matsukuma KE, et al. Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015;39(12):1653–1660.
   PubMed Web of Science ®Google Scholar
• Weidner A-S, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39(12):1661–1667.
   PubMed Web of Science ®Google Scholar
• Brown, J. R., M. J. Hallek, and J. M. Pagel. "Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination?." In American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting. 2016;35:e387-98.
   Google Scholar
• Molica S. Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future. Expert Review of Hematology. 2017;10(5):425–432.
   Google Scholar
• ZYDELIG®. Full prescribing information. 2014.
   Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559–3566.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the cll8 trial. Blood. 2015;127(2):208–215.
   PubMed Web of Science ®Google Scholar
• Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–1924.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309.
   PubMed Web of Science ®Google Scholar
• Mato A, Hill B, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050–1056.
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Barr PM, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199–2205.
   PubMed Web of Science ®Google Scholar
• Jones J, Choi MY, Mato AR, et al. Venetoclax (ven) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood. 2016;128(22):637–637.
   Web of Science ®Google Scholar
• Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127(3):279–286.
   PubMed Web of Science ®Google Scholar